Fig. 1From: Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective studyFlow diagram demonstrating the methods used for the identification of this study to retrospectively assess the efficacy and safety of nivolumab plus ipilimumab (NPI) versus nivolumab alone (NIV) in individuals with untreated programmed death-ligand 1 (PD-L1) positive MSTSBack to article page